Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) have received an average rating of “Moderate Buy” from the eighteen ratings firms that are currently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell rating, two have given a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $57.8235.

A number of brokerages have weighed in on RARE. Morgan Stanley lifted their price target on shares of Ultragenyx Pharmaceutical from $50.00 to $67.00 and gave the company an “overweight” rating in a research note on Thursday, April 16th. Weiss Ratings raised shares of Ultragenyx Pharmaceutical from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Thursday, July 9th. Guggenheim cut their price objective on shares of Ultragenyx Pharmaceutical from $43.00 to $35.00 and set a “buy” rating on the stock in a research report on Tuesday, August 4th. Cantor Fitzgerald upped their target price on shares of Ultragenyx Pharmaceutical from $84.00 to $96.00 and gave the stock an “overweight” rating in a research note on Thursday, May 21st. Finally, HC Wainwright reaffirmed a “buy” rating and issued a $50.00 target price on shares of Ultragenyx Pharmaceutical in a research note on Monday.

Insider Transactions at Ultragenyx Pharmaceutical

In other news, Director Shehnaaz Suliman sold 5,740 shares of the business’s stock in a transaction dated Monday, May 18th. The stock was sold at an average price of $25.12, for a total value of $144,188.80. Following the sale, the director directly owned 27,951 shares in the company, valued at $702,129.12. The trade was a 17.04% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CFO Howard Horn sold 4,653 shares of the company’s stock in a transaction dated Monday, June 1st. The stock was sold at an average price of $23.77, for a total value of $110,601.81. Following the transaction, the chief financial officer directly owned 105,689 shares of the company’s stock, valued at $2,512,227.53. This represents a 4.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders have sold 14,292 shares of company stock valued at $351,644. 5.20% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Ultragenyx Pharmaceutical

Several hedge funds have recently made changes to their positions in the business. Sanctuary Advisors LLC bought a new stake in shares of Ultragenyx Pharmaceutical in the second quarter worth $207,000. Connor Clark & Lunn Investment Management Ltd. bought a new position in Ultragenyx Pharmaceutical in the second quarter valued at $6,397,000. Commerce Bank bought a new position in Ultragenyx Pharmaceutical in the second quarter valued at $403,000. Quantbot Technologies LP acquired a new stake in Ultragenyx Pharmaceutical in the 2nd quarter valued at $48,000. Finally, Landscape Capital Management L.L.C. bought a new stake in Ultragenyx Pharmaceutical during the 2nd quarter worth about $223,000. 97.67% of the stock is owned by institutional investors.

Key Stories Impacting Ultragenyx Pharmaceutical

Here are the key news stories impacting Ultragenyx Pharmaceutical this week:

• Positive Sentiment: HC Wainwright reaffirmed its Buy rating and $50 price target for Ultragenyx, implying substantial upside from recent trading levels. Ultragenyx Pharmaceutical Earns Buy Rating from HC Wainwright
• Positive Sentiment: The firm sharply raised its Q3 2026 EPS forecast to $0.75 from a projected loss of $0.84 and increased Q4 2026 EPS to $0.78 from a loss of $0.35. Its FY2026 loss estimate also improved to $1.18 per share from $4.27, suggesting stronger near-term profitability expectations.
• Neutral Sentiment: Analyst price targets compiled by brokerages were reported at an average of $57.82, although the article did not identify a specific change in the broader consensus. Brokerages Set Ultragenyx Pharmaceutical Price Target
• Negative Sentiment: HC Wainwright reduced its FY2027 EPS forecast to $4.50 from $5.61. Quarterly estimates were also cut for Q1 2027, to $0.06 from $0.27; Q2 2027, to $0.91 from $1.18; Q3 2027, to $1.25 from $1.54; and Q4 2027, to $2.27 from $2.63. These revisions signal slower expected earnings growth beyond 2026 and likely explain the cautious stock reaction.

Ultragenyx Pharmaceutical Price Performance

NASDAQ RARE opened at $26.38 on Friday. The firm has a market cap of $2.60 billion, a P/E ratio of -4.52 and a beta of 0.35. The stock’s 50-day moving average is $28.22 and its 200-day moving average is $24.91. Ultragenyx Pharmaceutical has a one year low of $18.29 and a one year high of $39.89.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last issued its quarterly earnings data on Tuesday, August 4th. The biopharmaceutical company reported ($0.90) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.22) by $0.32. Ultragenyx Pharmaceutical had a negative return on equity of 1,024.42% and a negative net margin of 81.79%.The business had revenue of $214.00 million during the quarter, compared to analyst estimates of $183.08 million. During the same period in the previous year, the firm earned ($1.17) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 28.5% compared to the same quarter last year. Equities analysts anticipate that Ultragenyx Pharmaceutical will post -4.08 EPS for the current year.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc is a biopharmaceutical company focused on developing and commercializing therapies for rare and ultra-rare genetic disorders. Since its founding in 2010 and headquarters in Novato, California, the company has built expertise in protein replacement therapies, small molecules and gene therapy approaches to address high-unmet medical needs. Ultragenyx applies a precision medicine model, leveraging both in-house research and strategic collaborations to advance its product pipeline from discovery through regulatory approval.

The company’s commercial portfolio includes Crysvita (burosumab-tmyl) for X-linked hypophosphatemia, Mepsevii (vestronidase alfa-vjbk) for mucopolysaccharidosis VII and Dojolvi (triheptanoin) for long-chain fatty acid oxidation disorders.